The 2025 Intercepting Blood Cancers Workshop (IBC) will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

• Lymphoma, chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL)
• Multiple myeloma, smoldering myeloma (SMM) and monoclonal gammopathy of unknown significance (MGUS)
• Clonal hematopoiesis of indeterminate potential (CHIP), Myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and clonal cytopenia of undetermined significance (CCUS)

• Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
• Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
• Share knowledge and clinical insights between blood cancer disciplines and therapy areas
• Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks